Related Experiment Videos

Efficacy of long-term macrolide antibiotic therapy in patients with diffuse panbronchiolitis: comparison between

Jun-ichi Kadota1, Hiroshi Mukae, Kazunori Tomono

  • 1Department of Infectious Diseases, Division of Pathogenesis and Disease Control, Oita University Faculty of Medicine, 1-1 Hasama, Oita 879-5593, Japan. kadota@med.oita-u.ac.jp

International Journal of Antimicrobial Agents
|November 24, 2004
PubMed

Insights

This study found that long-term macrolide antibiotic therapy effectively improves diffuse panbronchiolitis (DPB) symptoms and lung function, regardless of HLA-B54 genetic status. Macrolide treatment benefits patients with DPB irrespective of genetic predisposition.

Area of Science:

  • Pulmonology
  • Genetics
  • Pharmacology

Background:

  • Diffuse panbronchiolitis (DPB) is a chronic airway inflammatory disease.
  • The role of human leukocyte antigen (HLA) B54 in DPB pathogenesis is unclear.
  • Long-term macrolide therapy is a standard treatment for DPB.

Purpose of the Study:

  • To compare clinical characteristics and treatment outcomes of long-term macrolide therapy in HLA-B54-positive versus HLA-B54-negative patients with DPB.
  • To investigate the influence of genetic predisposition on DPB treatment response.

Main Methods:

  • Retrospective analysis of 32 Japanese patients diagnosed with DPB.
  • Comparison of clinical, laboratory, radiological, and bacterial features between HLA-B54-positive and -negative groups before treatment.
  • Evaluation of treatment outcomes, including clinical symptoms, PaO(2), and forced expiratory volume in 1s (FEV(1)), after long-term macrolide therapy.

Main Results:

  • No significant differences in clinical, laboratory, radiological, or bacterial features were observed between the groups before therapy.
  • Long-term macrolide treatment led to comparable improvements in clinical symptoms, PaO(2), and FEV(1) in both HLA-B54-positive and -negative patients.
  • Macrolide therapy demonstrated efficacy irrespective of the patient's HLA-B54 antigen status.

Conclusions:

  • Genetic susceptibility, specifically HLA-B54 status, may not be a primary factor in the pathogenesis of DPB.
  • Low-dose macrolide therapy is an effective treatment for improving clinical outcomes in DPB patients, independent of their genetic predisposition.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...